GLP-1 drugs aren't insulin, and they aren't diabetes-only: what the evidence says

What did @_pharmablog_ actually say?

The caption does the heavy lifting here. The transcript itself is largely unintelligible, a garbled mix of English phrases that appears to be a failed auto-transcription of what was likely a German-language video. So let's be honest: we're fact-checking the written claims, not a reliably captured spoken argument.

In the caption, @_pharmablog_ makes two core assertions. First, "GLP-1 ist kein Insulin" (GLP-1 is not insulin). Second, that GLP-1 receptor agonists are "längst" (long since) used for obesity because they demonstrably help with weight management and reduce the risk of secondary conditions. The creator signals frustration, presumably at misconceptions circulating online. Those are the claims we can actually evaluate.

Does the science back this up?

On the biochemistry: yes, completely. GLP-1 receptor agonists and insulin are not the same drug class, do not share a mechanism, and conflating them is a real and common error worth correcting publicly.

GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone. Synthetic agonists like semaglutide and tirzepatide bind GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. They do not directly replace or mimic insulin itself. Insulin replaces a hormone the pancreas can no longer produce adequately. These are categorically different interventions.

On weight management: the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide 2.4 mg weekly produced mean body weight reduction of 14.9% versus 2.4% with placebo over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide achieved up to 22.5% mean weight reduction. These are not marginal effects.

The claim that GLP-1 drugs reduce risk of secondary conditions is also supported. The SELECT trial (Lincoff et al., 2023, NEJM) demonstrated semaglutide reduced major adverse cardiovascular events by 20% in people with obesity but without diabetes, which is a meaningful finding for a non-diabetic population.

What did they get wrong (or right)?

They got the core biochemistry right. GLP-1 agonists are not insulin. That correction is legitimate and worth making.

They also got the approved-use framing right. Wegovy (semaglutide 2.4 mg) has been approved by the EMA and FDA specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Calling it a "diabetes-only" drug in 2024 is simply outdated.

What the creator did not address, and what matters clinically, is the distinction between individual brand formulations. Ozempic (semaglutide 1 mg or 2 mg) is approved for type 2 diabetes in Germany. Wegovy is the obesity-specific formulation. These are the same molecule at different doses and with different regulatory indications. Blurring this risks patient confusion about which product applies to them.

No false claims about cures, dosing, or compounded equivalency appear in the caption. That's a low bar, but worth noting it was cleared.

What should you actually know?

GLP-1 receptor agonists are a drug class, not a single drug. Semaglutide, tirzepatide, and liraglutide all work on GLP-1 receptors but differ in structure, additional receptor targets (tirzepatide is a dual GIP/GLP-1 agonist), approved indications, and effect sizes.

The "not just for diabetes" framing is accurate but incomplete. Access in Germany through statutory health insurance (GKV) for obesity indications remains restricted, and prescribing outside approved indications carries regulatory weight. Patients watching TikTok summaries and concluding they qualify for these medications need a proper clinical assessment, not a caption.

Side effects matter and are underrepresented in social media content. Nausea, vomiting, and gastroparesis risk are real. The FAERS database has logged reports of severe gastroparesis in GLP-1 users without prior history. These drugs are effective and they carry meaningful risks that deserve more than a hashtag.

Verdict

The written claims in this video are largely accurate and worth saying out loud. GLP-1 drugs are not insulin. They are approved for obesity. The science on weight outcomes is solid. Where the video falls short is scope: a 30-second caption cannot carry the nuance that patients making treatment decisions actually need. Credit for getting the basics right. But social media health content that stops at "it works" without addressing access barriers, side effects, or which specific drug applies is doing half a job.